BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34954217)

  • 1. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
    Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK
    Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program.
    Sahlgren H; Elfström KM; Lamin H; Carlsten-Thor A; Eklund C; Dillner J; Elfgren K
    Am J Obstet Gynecol; 2020 Mar; 222(3):253.e1-253.e8. PubMed ID: 31585095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center.
    Domröse CM; Wieland U; Pilch H; Einzmann T; Schömig-Markiefka B; Mallmann P; Silling S; Mallmann MR
    J Low Genit Tract Dis; 2022 Apr; 26(2):122-126. PubMed ID: 35019900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus vaccination history and diagnosis of cervical intraepithelial neoplasia grade ≥2 severe lesions among a cohort of women who underwent colposcopy in Kaiser Permanente Southern California.
    Lonky NM; Xu L; Da Silva DM; Felix JC; Chao C
    Am J Obstet Gynecol; 2021 Dec; 225(6):656.e1-656.e11. PubMed ID: 34273278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
    Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
    Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Swede score colposcopy scoring system and histopathological results in patients with high-risk HPV infection other than HPV16 and 18.
    Alan M; Gunyeli I; Gultekin M; Sancı M; Yuce K
    Int J Gynecol Cancer; 2020 Jan; 30(1):35-40. PubMed ID: 31792083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
    Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
    Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
    Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
    BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands.
    Schurink-van 't Klooster TM; Siebers AG; Hoes J; van Kemenade FJ; Berkhof J; Bogaards JA; de Melker HE
    Cancer Med; 2023 May; 12(10):11786-11794. PubMed ID: 36965085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Test Performance of Cervical Cytology Among Adults With vs Without Human Papillomavirus Vaccination.
    Teoh D; Nam G; Aase DA; Russell R; Melton GB; Kulasingam S; Vogel RI
    JAMA Netw Open; 2022 May; 5(5):e2214020. PubMed ID: 35612854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Cervical Cytology and Histology Among Human Papillomavirus-Vaccinated and -Unvaccinated Women in an Academic Colposcopy Clinic.
    Dorton BJ; Vitonis AF; Feldman S
    Obstet Gynecol; 2015 Oct; 126(4):785-791. PubMed ID: 26348184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.
    Hu SY; Kreimer AR; Porras C; Guillén D; Alfaro M; Darragh TM; Stoler MH; Villegas LF; Ocampo R; Rodriguez AC; Schiffman M; Tsang SH; Lowy DR; Schiller JT; Schussler J; Quint W; Gail MH; Sampson JN; Hildesheim A; Herrero R;
    J Natl Cancer Inst; 2022 Sep; 114(9):1253-1261. PubMed ID: 35640980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of human papillomavirus genotype on colposcopic appearance: a cross-sectional analysis.
    van der Marel J; van Baars R; Quint WG; Berkhof J; del Pino M; Torné A; Ordi J; Wentzensen N; Schiffman M; van de Sandt MM; Lindeman J; Jenkins D; Helmerhorst TJ; Verheijen RH; ter Harmsel B; Alonso I
    BJOG; 2014 Aug; 121(9):1117-26. PubMed ID: 24494663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
    Lee GY; Inthasorn P; Laowahutanont P; Lawpoolsri S; Kamolratanakul S; Lungchukiet P; Oh J; Termrungruanglert W; Taechakraichana N; Pitisuttithum P
    Vaccine; 2022 Mar; 40(13):1968-1976. PubMed ID: 35190207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a Human Papillomavirus Vaccination Program within Organized Cervical Cancer Screening: Cohort Study.
    Martellucci CA; Morettini M; Brotherton JML; Canfell K; Manzoli L; Flacco ME; Palmer M; Rossi PG; Martellucci M; Giacomini G; D'Errico MM; Pasqualini F
    Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):588-594. PubMed ID: 35027435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion.
    Ryu KJ; Lee S; Min KJ; Kim JW; Hong JH; Song JY; Lee JK; Lee NW
    Oncologist; 2015 Jun; 20(6):635-9. PubMed ID: 25964305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.